Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Responding To Cybersecurity Threats: FDA Addresses Postmarket Questions In Draft Guidance

This article was originally published in The Gray Sheet

Executive Summary

FDA issued a draft guidance on how companies should monitor and respond to potential cybersecurity threats in the postmarket setting. Some cybersecurity problems will require a recall action, but in most cases urgent notification to FDA will not be necessary, the document suggests.

Advertisement

Related Content

FDA Says It Is Changing Its Cybersecurity Culture, And Others Should Too
FDA Proposal For Cybersecurity Info In Pre-market Submissions Generates Debate

Topics

Advertisement
UsernamePublicRestriction

Register